QUICK TAKE
The signal, without the leap.
FDA clarified how federal compounding restrictions apply as the national supply of approved GLP-1 medicines stabilizes. The agency emphasized that compounded drugs are not FDA approved and that routine copies of approved products do not fit the same framework as patient-specific or shortage-related compounding exceptions.
WHAT CHANGED
Key points from the source.
- 01
FDA's clarification addresses compounding under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
- 02
The agency states that semaglutide and tirzepatide are not on the 503B bulks list and that neither appears on FDA's drug-shortage list.
- 03
FDA-approved products undergo premarket review for safety, effectiveness, and quality; compounded drugs do not undergo that same premarket review.
- 04
The applicable analysis depends on the pharmacy or outsourcing facility, the ingredient, the clinical need, and the specific statutory conditions—not simply on demand for a lower-cost copy.
WHY IT MATTERS
The decision boundary.
Ingredient names alone blur a major product-quality distinction. An FDA-approved semaglutide or tirzepatide product and a compounded preparation are different regulatory objects.
Anyone evaluating access or product status should verify the current FDA shortage and compounding materials rather than relying on an older shortage-era explanation.
PRIMARY SOURCES